DCTH Stock - Delcath Systems Inc.

DCTH Stock Chart

DCTH Profile

Delcath Systems, Inc. is a specialized interventional oncology company that focuses on advancing the treatment options for primary and metastatic liver cancers across the United States and Europe. The company is prominently recognized for its innovative product, HEPZATO KIT, which integrates melphalan hydrochloride for injection within a hepatic delivery system. This unique system enables the targeted administration of high-dose chemotherapy directly to the liver, thereby minimizing systemic exposure and reducing associated side effects. This approach is particularly beneficial for patients requiring localized treatment while preserving overall systemic health.

At the forefront of Delcath's clinical endeavors is its HEPZATO clinical develllopment program, which includes the pivotal FOCUS trial. This trial is specifically designed to evaluate the objective response rate in patients with hepatic dominant ocular melanoma, a form of metastatic ocular melanoma. Through rigorous clinical investigations like the FOCUS trial, Delcath aims to demonstrate the efficacy and safety of HEPZATO in treating challenging liver cancers, ultimately improving outcomes for patients worldwide.

Beyond its clinical research initiatives, Delcath also markets HEPZATO as a stand-alone medical device under the brand name CHEMOSAT Hepatic Delivery System for Melphalan. This system is commercially available in Europe, allowing medical centers to utilize advanced hepatic delivery technologies to treat a wide spectrum of liver cancers effectively. By providing healthcare professionals with innovative tools like the CHEMOSAT system, Delcath supports the personalized treatment of liver cancer, addressing the critical need for targeted therapies that enhance patient outcomes.

Founded in 1988 and headquartered in New York, New York, Delcath Systems continues to drive innovation in interventional oncology. With a dedicated focus on liver cancer treatments and leveraging its proprietary technologies, the company is committed to advancing therapeutic options that offer new hope and improved quality of life for patients facing complex oncological challenges.

DCTH Revenue Chart

DCTH Earnings

Analyst Ratings